Lanteri Charlotte A, Tidwell Richard R, Meshnick Steven R
Department of Pathology and Laboratory Medicine, University of North Carolina, 2102C McGavran/Greenberg Hall, Chapel Hill, NC 27599, USA.
Antimicrob Agents Chemother. 2008 Mar;52(3):875-82. doi: 10.1128/AAC.00642-07. Epub 2007 Dec 17.
Human African trypanosomiasis (HAT) is a fatal tropical disease caused by infection with protozoans of the species Trypanosoma brucei gambiense and T. b. rhodesiense. An oral prodrug, DB289, is a promising new therapy undergoing phase III clinical trials for early-stage HAT. DB289 is metabolically converted to the active trypanocidal diamidine DB75 [2,5-bis(4-amidinophenyl)furan]. We previously determined that DB75 inhibits yeast mitochondrial function (C. A. Lanteri, B. L. Trumpower, R. R. Tidwell, and S. R. Meshnick, Antimicrob. Agent Chemother. 48:3968-3974, 2004). The purpose of this study was to investigate if DB75 targets the mitochondrion of T. b. brucei bloodstream forms. DB75 rapidly accumulates within the mitochondria of living trypanosomes, as indicated by the fluorescent colocalization of DB75 with a mitochondrion-specific dye. Fluorescence-activated cell sorting analysis of rhodamine 123-stained living trypanosomes shows that DB75 and other trypanocidal diamidines (pentamidine and diminazene) collapse the mitochondrial membrane potential. DB75 inhibits ATP hydrolysis within T. brucei mitochondria and appears to inhibit the oligomycin-sensitive F 1 F 0-ATPase and perhaps other ATPases. DB75 is most likely not an inhibitor of electron transport within trypanosome mitochondria, since DB75 fails to inhibit mitochondrial respiration when glycerol-3-phosphate is used as the respiratory substrate. However, DB75 inhibits whole-cell respiration (50% inhibitory concentration, 20 microM) at drug concentrations and incubation durations that also result in the dissipation of the mitochondrial membrane potential. Taken together, these findings suggest that the mitochondrion is a target of the trypanocidal action of DB75.
人类非洲锥虫病(HAT)是一种由布氏冈比亚锥虫和布氏罗得西亚锥虫这两种原生动物感染引起的致命热带疾病。口服前药DB289是一种有前景的新疗法,正在进行针对早期HAT的III期临床试验。DB289经代谢转化为具有杀锥虫活性的双脒DB75 [2,5-双(4-脒基苯基)呋喃]。我们之前确定DB75会抑制酵母的线粒体功能(C. A. 兰特里、B. L. 特朗普沃尔、R. R. 蒂德韦尔和S. R. 梅什尼克,《抗菌药物化疗》48:3968 - 3974,2004年)。本研究的目的是调查DB75是否靶向布氏冈比亚锥虫血流形式的线粒体。如DB75与线粒体特异性染料的荧光共定位所示,DB75在活锥虫的线粒体内迅速积累。对罗丹明123染色的活锥虫进行荧光激活细胞分选分析表明,DB75和其他杀锥虫双脒(喷他脒和二脒那嗪)会使线粒体膜电位崩溃。DB75抑制布氏冈比亚锥虫线粒体内的ATP水解,似乎还抑制对寡霉素敏感的F1F0 - ATP酶以及可能的其他ATP酶。DB75很可能不是锥虫线粒体电子传递的抑制剂,因为当以3 - 磷酸甘油作为呼吸底物时,DB75无法抑制线粒体呼吸。然而,在导致线粒体膜电位消散的药物浓度和孵育时间下,DB75会抑制全细胞呼吸(50%抑制浓度,20 microM)。综上所述,这些发现表明线粒体是DB75杀锥虫作用的靶点。